Tirzepatide vs Liraglutide: Which Is Right for You?
Both are FDA-approved for weight management. Tirzepatide (Zepbound) is a once-weekly GIP and GLP-1 receptor agonist; liraglutide (Saxenda) is a once-daily GLP-1 receptor agonist. In separate pivotal trials tirzepatide 15 mg produced −20.9% at 72 weeks and liraglutide 3.0 mg −8.0% at 56 weeks.
Side-by-side comparison
| Tirzepatide | Liraglutide | |
|---|---|---|
| Receptors | GIP + GLP-1 | GLP-1 |
| Dosing frequency | Once weekly | Once daily |
| Weight brand | Zepbound | Saxenda |
| Maker | Eli Lilly | Novo Nordisk |
| Pivotal result | −20.9% at 72 wk (SURMOUNT-1, 15 mg) | −8.0% at 56 wk (SCALE, 3.0 mg) |
| FDA status | Approved | Approved; generic available |
Complete comparison (2026)
Key takeaways
- These are cross-trial numbers from different populations and durations, not a head-to-head result.
- Both labels carry the boxed thyroid C-cell tumor warning.
- Liraglutide is available as a generic; tirzepatide is brand-only.
What are Tirzepatide and Liraglutide?
Tirzepatide is a once-weekly peptide from Eli Lilly that activates both GIP and GLP-1 receptors; it is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnea with obesity.
Liraglutide is a once-daily GLP-1 receptor agonist, FDA-approved as Victoza and Saxenda; generic versions are available.
Mechanism differences
Liraglutide activates only the GLP-1 receptor. Tirzepatide is a single peptide that activates both GIP and GLP-1 receptors.
Effectiveness
SURMOUNT-1 (NEJM 2022) reported −15.0%, −19.5% and −20.9% with tirzepatide 5, 10 and 15 mg versus −3.1% with placebo at 72 weeks. SCALE Obesity and Prediabetes (NEJM 2015) reported −8.0% with liraglutide 3.0 mg versus −2.6% with placebo at 56 weeks.
Side effect profiles
Both are dominated by gastrointestinal effects (nausea, diarrhea, vomiting, constipation), which are most common during dose escalation. Both labels warn about pancreatitis and gallbladder disease.
Dosing & administration
Zepbound starts at 2.5 mg weekly and rises in 2.5 mg steps every 4 weeks to a maximum of 15 mg. Saxenda starts at 0.6 mg daily and rises weekly to 3.0 mg daily. See the labels.
Cost
Liraglutide has generic versions; tirzepatide is brand-only. We link to live pricing rather than quote numbers.
FDA & regulatory status
Both FDA-approved. Compounded or "research" versions are not the approved products.
Who should choose which
A prescriber weighs health history, tolerability, injection frequency, coverage and supply. Nothing here is a recommendation.
What the evidence does not show
- A head-to-head weight-loss comparison of these two drugs.
- Equivalence of compounded products to the approved drugs.
Frequently asked questions
Is tirzepatide stronger than liraglutide?
Tirzepatide produced larger average weight loss in its pivotal trial than liraglutide did in its own, but the trials differ, so this is not a direct comparison.
Is there generic liraglutide?
Yes. Generic liraglutide (the Victoza molecule) launched in the US in 2024.
Can they be taken together?
No. The Zepbound label says not to use it with other GLP-1 receptor agonists.
References
Find a clinic
Our clinic directory lists only clinics whose address and services we confirmed on their own websites, with the date we checked.